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ABSTRACT
After the introduction of the rotavirus vaccine, the number of rotavirus-associated deaths 
and the predicted annual rotavirus detection rate had slightly declined worldwide. Taking in 
account that in Colombia, Rotarix vaccine was introduced in 2009, the purpose of this study 
was to evaluate the presence of rotavirus A in children under five years who were treated 
for acute diarrhoea in Bucaramanga, Colombia and, moreover, to determine the genotypes 
of rotavirus present in those children. We performed an analytical cross-sectional study 
of rotavirus A in faecal samples from children up to five years of age. Stool samples were 
screened for rotavirus A using a lateral-flow immunochromatographic assay and confirmed 
using a VP6 sandwich ELISA. Genotyping of rotavirus A-positive samples was performed 
by PCR and sequencing of VP7 and VP4 genes. The overall prevalence of rotavirus was 
30.53% (95% confidence interval [CI] 21.2 - 39.7). Most of the children with rotavirus 
(86.2%) had received two doses of the rotavirus vaccine. G3 strains accounted for the vast 
majority of cases (82.8%), followed by G12 strains (13.8%) and G3/G9 coinfections (3.4%). 
Among the P genotypes, P[8] was the most prevalent (69%), followed by P[9] (31%). The 
most common G[P] genotype combination was G3P[8], followed by G3P[9]. The main 
finding in this study was that rotavirus, in a Colombian region, is still an important pathogen 
in children under five years old, previously vaccinated. The results showed that different 
factors, such as kindergarten attendance, could explain the epidemiology and transmission 
of rotavirus in Bucaramanga.
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INTRODUCTION
Acute diarrhoea (defined by the occurrence of three or more loose, liquid, 
or watery stools or at least one bloody loose stool in a 24 h period1) is one of 
the most common diseases in infants and young children in both, developed and 
developing countries2. The incidence of diarrhoea in African, Latin American and 
Asian countries in children under 5 years of age has been estimated to be over one 
billion, with approximately 3.3 million deaths per year3. Rotavirus A is considered 
one of the most important causes of severe acute gastroenteritis in infants and 
young children in both, developed and developing countries4. In the pre-vaccination 
era, estimates indicated that rotavirus A caused 111 million episodes of diarrhoea 
requiring only home care, 25 million clinic visits, 2 million hospitalizations, and 
325,000-592,000 deaths (a median of 440,000 deaths) in children under 5 years of 
age (per year), primarily in developing countries5.
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In 2009, the World Health Organization (WHO) 
recommended the global introduction of rotavirus vaccines in 
national immunization programs6. Post-vaccine introduction 
analysis showed that the number of rotavirus A-associated 
deaths in children under 5 years of age declined globally 
from 528,000 (95% confidence interval 465,000-591,000) 
in 2000 to 215,000 (range, 197,000-233,000) in 2013, and 
the predicted annual rotavirus detection rate declined slightly 
over time from 42.5% to 37.3%, globally7. In the most recent 
analysis, rotavirus was responsible for an estimated 128,500 
deaths (95% confidence interval 104,500-155,600) among 
children younger than 5 years throughout the world and 
has been responsible for more than 258 million episodes of 
diarrhoea among children (95% interval 193 -341 million), 
concluding that rotavirus-associated mortality has decreased 
markedly over time in part because of the introduction of 
the rotavirus vaccine8. Before the introduction of rotavirus 
vaccine in Latin America, more than 15,000 deaths annually 
were related to rotavirus A infections; however, recent reports 
from Latin American countries have shown a decline in 
mortality due to diarrhoea after the rotavirus vaccine was 
implemented9,10. For example, an in-hospital surveillance 
system indicated that in Colombia (before the introduction 
of vaccination, in January 2009) the rotavirus infection was 
the cause of approximately 50% of the hospitalizations 
due to diarrhoea11. Specifically in Bucaramanga City 
(the Northeastern region of Colombia), prior to vaccine 
introduction, rotavirus A was the main cause of diarrhoeal 
disease in children under five years who consulted emergency 
services, accounting for 44.4% (95% confidence interval [CI] 
37.1-52.0) of the cases12. However, since the introduction 
of vaccination, the presence of rotavirus A as a pathogen in 
children under five years, consulting for acute diarrhoea has 
not been evaluated. Therefore, the purpose of this study was 
to evaluate the presence of rotavirus A in children under five 
years who were treated for acute diarrhoea in Bucaramanga, 
Colombia. In addition, we determined the various genotypes 
of rotavirus present in those children.
MATERIALS AND METHODS
Ethics statement
This study was conducted in accordance with the 
Declaration of Helsinki. The Research and Ethics 
Committees of the Universidad Cooperativa de Colombia 
(Act Nº 6, July 7, 2014) and of the Bucaramanga 
Institute of Health – ISABU (Rad Nº 002537, March 
18, 2015) approved this study. We applied the STROBE 
(STrengthening the Reporting of OBservational studies in 
Epidemiology) procedures for the observational studies. 
The samples and results were identified and analysed 
anonymously. All caretakers of the children enrolled who 
agreed to participate signed a written consent form approved 
by the ethics board. After a caretaker had signed the written 
consent form to participate in the study, nursing personnel 
used a standardized data collection form to obtain critical 
information, such as the place of residence, age, sex, feeding 
history, presence and duration of fever and/or vomiting, 
consistency and frequency of stool, and diarrhoea duration 
in the last 24-48 h. Participants were asked if there was 
any history of a neighbour with diarrhoea and if they had 
contact with farms or farm animals, as well as about the 
caretakers’ professions, among other questions. Vaccine 
coverage was asked and confirmed by the review of the 
children’s vaccination cards. 
Study settings
Study design and population
We developed an analytical cross-sectional study on the 
presence of rotavirus A in faecal samples of children up to 
5 years of age who presented with acute gastroenteritis. 
Case definition
A case of acute diarrhoea was defined by the occurrence 
of three or more loose, liquid, or watery stools or at least 
one bloody loose stool in a 24 h period1.
Sampling
The samples (95 stool samples) were collected in two 
public hospitals belonging to the Bucaramanga Institute of 
Health - ISABU in the Northeastern region of Colombia 
(Figure 1).
Study period
The samples were collected between June 2015 and 
January 2016, which was determined to be sufficient to 
provide a confidence level of 95%, a margin of error of 
10%, and an expected prevalence of 44%.
Laboratory methods
We used immunological tests to identify and confirm 
faecal samples positivity to rotavirus and molecular analysis 
to classify the circulating genotypes, as we describe below.
Identification of rotavirus-positive samples by 
immunological tests
As soon as the stool samples arrived at the laboratory, 
they were split into three aliquots and immediately frozen at 
-70 °C. According to the WHO recommendations, all stool 
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samples were screened for rotavirus A using a commercially 
available lateral-flow immunochromatographic assay (The 
Rida Quick Rotavirus/Adenovirus Combi, r-Biopharm, 
Darmstadt, Germany) that used labelled monoclonal 
antibodies against rota- and adenoviruses surface antigens. 
Positive samples were confirmed using a second aliquot 
of the stool in an ELISA assay that employed monoclonal 
antibodies for rotavirus group-specific antigen (VP6) 
using a sandwich-type method (Ridascreen ELISA tests 
of r-Biopharm). Both methods were performed according 
to the manufacturer’s instructions.
Identification of circulating genotypes by molecular 
analysis
RNA extraction
Stool suspensions (10%) were prepared in 0.01 M 
phosphate-buffered saline (PBS) (pH 7.2), vortexed and 
centrifuged. The supernatant was filtered using a 0.22-µm 
filter and transferred to a sterile centrifuge tube. The total 
RNA was extracted from 140 µL of the faecal suspension 
using the QIAamp Viral RNA extraction kit (QIAGEN, 
Hilden, Germany) according to the manufacturer’s 
instructions. The RNA quality and quantity were determined 
spectrophotometrically by using a NanoDrop ND-1000 
spectrophotometer (Thermo Fisher Scientific Inc., Waltham, 
MA, USA) with 1 µL of sample. RNA aliquots were stored 
at -70 ºC until used in PCR assays.
Complementary DNA (cDNA) synthesis
Synthesis of cDNA was performed using the RevertAid™ 
Premium First Strand cDNA Synthesis Kit (Thermo 
Scientific® Glen Burnie, MD, USA) according to the 
manufacturer’s instructions. Briefly, a denaturation mix 
consisting of 1 µL (100 pmol/µL) of random hexamers, 
1 µL of dNTP mix (10 mM), and 13 µL (0.02-4.6 µg) 
of total RNA was initially denatured at 65 °C for 5 min 
and immediately incubated on ice. The RT mix solution 
contained 4 µL of 5X RT Buffer and 1 µL of RevertAid™ 
Premium Enzyme Mix. The RT mix was added to the 
denaturation mix, and reverse transcription was performed 
in a total volume of 20 µL in a Thermal Cycler for 10 min 
at 25 °C, followed by 60 min at 42 ºC. The reaction was 
stopped by heating to 85 °C for 5 min. The reaction product 
was stored at -80 ºC until used.
Genotyping by PCR
Following the procedures described by the WHO 
Rotavirus collaborating Center in Atlanta, Georgia, USA, 
for rotavirus detection and characterization13, we performed 
the PCR based on the amplification of the VP7 and VP4 
genes by using a primer set specific for each segment, 
followed by a second semi-nested amplification reaction 
using a mixture of specific primers for each genotype (i.e., 
specific internal primers for genotypes G1, G2, G3, G4, G9, 
and G12 and internal primers for genotypes P4, P6, P8, and 
P11) (Table 1). The initial amplification conditions included 
denaturation at 95 °C for 15 min and 30 cycles, as follows: 
denaturation at 94 °C for 30 s, annealing at 42 °C for 30 s, 
extension at 72 °C for 1 min, and extension at 72 °C for 
7 min. The conditions for the second amplification of G 
and [P] genotypes were 1 cycle of denaturation at 94 °C 
for 3 min and 30 cycles, as follows: denaturation at 94 °C 
for 40 s, annealing at 45 °C for 30 s, extension at 72 °C for 
1 min, and extension at 72 °C for 7 min. The amplified DNA 
was visualized by TAE electrophoresis in buffer (4 mmol/L 
Figure 1 - Geographical location of the sampling site in Colombia. The pink area denotes Santander Province, and the blue area 
denotes Bucaramanga City. The map was created using the DIVA-GIS software, version 7.5.0 for Windows™. 
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Tris-acetate, 1 mmol/L EDTA pH 8.0). Electrophoresis was 
performed in agarose gels at 100–120 V for 60 min, and the 
bands were observed using the EZ-VISION™ (Amresco® 
Solon, OH, USA) coupled to a UV transilluminator (Mini 
BIS Pro, DNR Bio Imaging. Systems, Jerusalem, Israel). 
The molecular weights of amplification products were 
estimated using a molecular weight ladder ranging from 
100 to 3000 bp (GeneRuler™ 100 bp Plus DNA Ladder, 
Thermo Scientific®) with the DNR GelCapture® software 
(DNR Bio-imaging System, Ltd., Israel).
G and P-genotyping confirmation by sequencing
One step RT-PCR was carried out using the SuperScript® 
III One-Step RT-PCR System with Platinum® Taq 
DNAPolymerase. (Life Technologies™, Paisley, UK). Each 
reaction was performed by adding 12.5 µL 2× reaction 
mix, 1 µL of the enzyme, 1 µL of primers (10 µM), 
0.5 µL of the extracted RNA and nuclease-free water. 
The amplification conditions included 60 °C for 30 min, 
94 °C for 2 min followed by 45 cycles of 94 °C for 15 s, 
55 °C for 30 s, 68 °C for 2 min and a final extension of 
68 °C for 5 min. We amplified a 1,062-bp fragment of 
the VP7 gene with the consensus forward primer Beg9 
(5’-GGCTTTAAAAGAGAGAATTTCCGTCTGG-3’) 
and the reverse primer End9 (5’-GGTCACATCATACAA 
TTCTAATCTAAG-3’)14. For the VP4 sequencing, the 
con3/F and con3/R amplification (Table 1) were used 
as the template DNA. The amplicons of RT-PCR were 
purified and sequenced by Macrogen Inc. (Seoul, Korea) 
in an ABI 3730xl automated sequencer. To confirm the G 
genotypes, the sequences obtained were compared with 
various prototype strains of each G-genotype by using 
BLAST™ and the RotaC v2.0 automated genotyping tool 
for Group A rotaviruses.
Statistical analysis
Data were analyzed using the software Prism® 7.01 
for Windows™ (GraphPad Software, San Diego, CA). 
Descriptive statistics of the demographic data were 
generated. Categorical variables are summarized as 
frequencies and proportions, and continuous variables are 
summarized where appropriate as means or medians with 
their measures of dispersion. A bivariate analysis to compare 
the rotavirus-positive and -negative patient characteristics 
was performed using the chi-square test or the Fisher’s exact 
test. Normality was verified using the Shapiro-Wilk test, and 
differences between continuous variables were calculated 
using the Mann-Whitney test. In all cases, P values < 0.05 
were considered statistically significant.
RESULTS
Between June 2015 and January 2016, 95 faecal samples 
from a group of children with diarrhoea were obtained from 
the ISABU. The entire population was composed of children 
with an average age of 19 months (range, 1 to 55 months). 
No gender prevalence was evidenced (51.6% female, 48.4% 
male). All children enrolled in the study were admitted to the 
hospital presenting with signs of acute gastroenteritis and 
acute diarrhoea (watery [39%], semiliquid [61%]) and in 
some cases bloody stools [29.4%]. The average number of 
diarrhoea episodes in the 24 hours prior to hospital admission 
was seven episodes (range, 4 to 15), the frequency of vomiting 
was reported as 75%, and fever was present in 78% of the 
children. Clinical dehydration (defined according to the 
WHO15) was found in only 14% of the children, and 6.31% 
of the enrolled children required hospitalization.
Regarding vaccine coverage, 87% of the children were 
found to have had at least one dose of rotavirus vaccine. 
Most children vaccinated against rotavirus had received two 
doses (87% of the total vaccinated children), while only 
13% had received one dose. Among the children under 9 
months of age, 31.45% had received one dose of rotavirus 
vaccine and 68.6% had received two doses of rotavirus 
vaccine.
Table 1 - Primers used for PCR genotyping. The sequences are 
in accordance with those reported by the WHO.
Primer Sequence (5’ to 3’)
First-amplification consensus primers G
9con1/F TAG CTC CTT TTA ATG TAT GG
9con2/R GTA TAA AAT ACT TGC CAC CA
Second-amplification genotyping primers G
9T-1 TCT TGT CAA AGC AAA TAA TG
9T-2 GTT AGA AAT GAT TCT CCA CT
9T-3 GTC CAG TTG CAG TGT AGC
9T-4 GGG TCG ATG GAA AAT TCT
9T-9 TAT AAA GTC CAT TGC AC
G12B CCG ATG GAC GTA ACG TTG TA
First-amplification consensus primers P
con3/F TGG CTT CGC TCA TTT ATA GAC A
con3/R ATT TCG GAC CAT TTA TAA CC
Second amplification (including VP7-Rdeg) P
1T-1 TCT ACT TGG ATA ACG TGC
2T-1 CTA TTG TTA GAG GTT AGA GTC
3T-1 TGT TGA TTA GTT GGA TTC AA
4T-1 TGA GAC ATG CAA TTG GAC
ND2 AGC GAA CTC ACC AAT CTG
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The overall prevalence of rotavirus A measured by 
the immunochromatographic was 30.53% (95% CI, 
21.2-39.7%). Moreover, all positive samples were confirmed 
by ELISA with a concordance of 100%between these two 
tests. . Most of the rotavirus-positive children had received 
two doses of rotavirus vaccine (86.2%), 6.9% had received 
at least one dose and 6.9% did not have a vaccination card 
to confirm rotavirus vaccination.
Among the rotavirus A-infected children, diarrhoea, 
fever and vomiting were the most common symptoms, 
present in 100%, 86% and 79% of the rotavirus-positive 
children, respectively. Dehydration among the rotavirus-
positive children was present in 24% of the patients, 
and 14% of these children required hospitalization. A 
significantly greater number of diarrhoea episodes were 
present in the children who were positive for rotavirus 
(7.857 ± 0.574) compared to the rotavirus-negative children 
(6.6 ± 0.2956) with a p value 0.0375.
The chi-square test was used to compare the rotavirus-
positive and -negative children enrolled in the study 
according to different factors. We did not find any difference 
between rotavirus-positive and rotavirus-negative children 
when they were compared by gender, fever, vomiting and 
hospitalization. Factors associated with rotavirus positivity 
are shown in Table 2. Kindergarten care (p=0.0108) was 
significantly associated with rotavirus diarrhoea, and no 
association was found with breastfeeding, living with 
animals or contact with adults who had diarrhoea.
An examination of the distribution of cases by age 
indicated that most of the rotavirus A-positive cases (51.7%) 
occurred in infants aged between 12 and 36 months, whereas 
only 17.23% of cases occurred during the first 12 months 
of life (Figure 2A and 2B). None of the children under 
6 months of age were confirmed as rotavirus A-positive. 
When we compared the ages of rotavirus-positive and 
-negative children, we found that the rotavirus-positive 
children were significantly older than the rotavirus-negative 
children (24.83±2.331, p=0.0009), as shown in Figure 2C 
and Table 2. However, we did not find any statistical 
difference when we compared each of the individual age 
groups between rotavirus A-positive and negative cases 
(data no shown).
Molecular confirmation of the rotavirus circulation
All ELISA rotavirus-positive samples were confirmed 
and genotyped by molecular techniques via amplification 
of the VP7 and VP4 genes using specific primers for each 
segment, followed by a second semi-nested amplification 
using a mixture of specific primers for each genotype 
(Table 1). Due to the fact that some G-types could not be 
typed by this technique, all G samples were re-amplified by 
using consensus VP7 primers and then sequenced.
Among the G-types, G3 strains (82.8%) accounted 
for the vast majority of cases, followed by the G12 
strains (13.8%) and G3/G9 coinfections (3.4%). Among 
Table 2 - Characteristics of the enrolled children with acute diarrhoea according to rotavirus positivity or negativity. 
Rotavirus-positive 
(N=29)
Rotavirus-negative 
(N=66) P value
Factor
Boys/girls (%/%) 44.8 / 55.2 50.8 / 49.2 0.2723a
Age, months (mean ± std. error) 24.83 ± 2.331 16.09 ± 1.65 0.0009b*
Birth weight, gr. (mean ± std. error) 3,262 ± 151.5 3,271 ± 78.78 0.7180b
Associated factors
Breastfeeding (%) 96.50 95.40 >0.9999c
Living with animals (%) 55.17 73.85 0.1201a
Kindergarten care (%) 41.37 16.92 0.0108a*
Contact with adults with diarrhoea (%) 10.34 12.3 >0.9999c
Clinical data
Diarrhoea episodes/24 hours (mean ± std. error) 7.86 ± 0.57 6.6 ± 0.29 0.0375b*
Children with fever (%) 82.75 75.38 0.5932c
Children with vomit (%) 79.31 72.30 0.472a
Clinical dehydration at admittance (%) 24.13 9.23 0.0531a
Requires hospitalization (%) 13.79 3.07 0.1967c
P<0.05 = statistically significant. a Chi-square test. b Mann-Whitney test. c Fisher’s exact test
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the P genotypes, P[8] was the most prevalent (69%), 
followed by P[9] (31%). The most common G[P] genotype 
combination was G3P[8] (58.6%), followed by G3P[9] in 
24.1% of the cases (Table 3). The monthly predominance 
of G3 and P[8] genotypes can be observed in Figures 3A 
and 3B, respectively.
DISCUSSION
Despite the global introduction of vaccines, rotavirus 
A is still one of the most important causes of acute 
diarrhoea in most of the world, and the efficacy, safety, 
and strain-specific effectiveness of the vaccine must be 
closely monitored in post-licensure surveillance programs. 
The purpose of this study was to determine the presence 
(prevalence and genotypes) of rotavirus A in children under 
5 years of age with acute gastroenteritis in the Northeastern 
region of Colombia in the post-vaccination era. 
Although some countries in the region, such as 
Mexico, Brazil, Nicaragua, and Panama, have documented 
substantial decreases of 22-50% in mortality due to 
diarrhoea among children under 5 years of age following 
vaccine introduction16-19, a full global declining tendency in 
the rotavirus burden has not been observed. In fact, recent 
reports have shown that the predicted annual rotavirus 
detection rate declined over time from 42.5% in 2000 
to 37.3% in 2013, globally7. However until the moment, 
there are no reports about the prevalence of rotavirus in the 
post-vaccination era in Colombia. Taking into account the 
Figure 2 - Age distribution of children under 5 years old. 
(A) Distribution of rotavirus positive/negative cases by age; 
(B) Distribution of rotavirus-positive children. The numbers 
on the bars indicate the exact percentage of patients with 
rotavirus diarrhoea. The numbers on the arrows indicate the 
cumulative percentage by age rank; (C) The Tukey box plot 
shows a comparison between rotavirus-positive and -negative 
children with respect to age. The P value obtained from the 
Mann-Whitney test indicates that there is statistical significance.
Table 3 - Distribution of G and [P] genotypes and circulating 
genotype combinations in children under 5 years old in the 
Northeastern region of Colombia.
Genotype G[P]
% of cases with the [P] genotype / 
(Number of samples)
P[8] P[9]
G3 58.6 (17) 24.1 (7)
G3 / G9 3.4 (1) 0 (0)
G12 6.9 (2) 6.9 (2)
Figure 3 - Monthly rotavirus A genotype confirmation. 
Genotypes G (A) and P (B) rate distribution are depicted.
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rotavirus A prevalence found in our study (30.53%, 95% 
CI 21.2-39.7%) and the few studies reported previously, 
we can speculate that the vaccination could be reducing 
the prevalence of the infection in Colombia. However, 
it is important to mention that the results of this study 
may not be a true reflection of the rotavirus burden in the 
Colombian community because the study was conducted 
with hospital-based samples, and it is well known that 
rotavirus A-positive cases are usually more severe and likely 
to be more representative in that type of study.
Before rotavirus vaccination, the National Institute of 
Health of Colombia (official institution of public health 
in Colombia) reported that almost 50% of acute diarrhoea 
cases in children under five years old could have been 
caused by rotavirus A11. Studies from other non-official 
institutions in different Colombian cities had implicated 
rotavirus A as the cause of acute diarrhoea in 37%-55% 
of cases11. More recently, in the Northeastern region of 
Colombia, rotavirus A was found to be the main cause of 
diarrhoeal disease in children under five years old who 
consulted emergency services, accounting for 44.4% of 
cases20. 
Our results regarding the vaccine coverage (87%) 
fully agree with previous results presented by Cotes et 
al. in 201321, who reported a coverage with a single dose 
of the rotavirus vaccine of 87.3% in a population survey 
carried out in five Colombian cities (Barranquilla, Bogota, 
Cali, Cartagena, and Riohacha). The monovalent rotavirus 
vaccine Rotarix® (GlaxoSmithKline Biologicals, Rixensart, 
Belgium) was introduced in the Expanded Program 
on Immunization in January 2009, and the previously 
mentioned studies were developed over the period from 
August through October 2010, which could indicate that 
the vaccine coverage has not increased in five years in 
the Northeastern region of Colombia, which should be 
evaluated by official health authorities. Higher rotavirus 
vaccine coverage could help to accomplish the fourth 
Millennium Development Goal proposed by the United 
Nations to reduce mortality by two-thirds in children under 
5 years old.
Multiple studies from developed and developing 
countries suggest that the rotavirus vaccine was effective, 
based on a 70% to 100% reduction in emergency department 
visits and hospitalizations of children with rotavirus acute 
gastroenteritis22,23. In Colombia, the effectiveness of the 
rotavirus vaccine in preventing hospitalization due to severe 
diarrhoea was 68%, and the percentage of hospitalizations 
due to rotavirus acute diarrhoea was reported to be greater 
than 5%21,24. Our results for the general population studied 
are close to this percentage (6.7%); however, in rotavirus-
positive children, we observed an important increase in 
the hospitalization rate, of 14% (Table 2), which should be 
assessed in the context of other comorbidities, nutritional 
status and socioeconomic issues. This clarification is 
important because malnutrition and a lack of access to 
appropriate hospital facilities have been reported as the 
main cause of increased mortality in children from low-
income countries9,10 
As indicated by our results, rotavirus-associated disease 
is characterized by fever, diarrhoea and vomiting, which 
are well known to lead to severe dehydration and increased 
hospitalization25. Rotavirus-positive, compared to -negative 
diarrhoea cases did not differ significantly when compared 
according to symptoms such as fever, vomiting or clinical 
dehydration in children at admission, in our study. However, 
the presence of these symptoms in diarrhoea cases has 
been shown to be associated with rotavirus-positivity in 
a number of studies from other settings26, contrary to our 
current observation. The high number of diarrhoea episodes 
in rotavirus-positive children (Table 2) increased the risk of 
dehydration and negative outcomes in the children.
In our region, prior to the rotavirus vaccine introduction, 
a higher incidence of rotavirus-associated diseases was 
seen in children between six and twelve months old12. Our 
results show an important increase in the rotavirus age 
distribution (24.83±2.331 months, p=0.0009 - Figure 2A). 
Although this is the first report of this phenomenon 
in Colombia, indicating a wider burden of rotavirus 
diseases, changes in the age distribution of children 
with rotavirus infections have been proposed in different 
models27 and have been reported in clinical studies in 
different countries28,29. In Philadelphia, USA, in 2010, 
a shift in the positivity to rotavirus infections toward 
older children was shown after the introduction of the 
rotavirus vaccine leading to a change in the median age 
of patients, from 11 months (range, 8-14 months) in 2008 
to 23 months in 200928. In a similar manner in Belgium, 
the percentage of all rotavirus A cases reported in children 
under one year of age declined from 53% to 26%, and 
an increase (from 30% in 2005-2006 to 40% in 2008) in 
children aged 12-23 months was observed29. In addition, 
an increased median age of patients hospitalized due to 
rotavirus-associated diarrhoea, from 14 months in 2006 to 
24 months in 2009, was reported in three US counties30. 
This important result needs to be confirmed by national 
epidemiological studies to completely understand the 
role of the rotavirus vaccine in the epidemiological shift 
of age distribution in infected children. This increase in 
the age group distribution of rotavirus A infections, has 
recently been reported in the increasing trend in children 
aged 25-48 months-old to become infected in Brazil after a 
decade of the introduction of vaccination with Rotarix®31.
Martinez-Gutierrez et al.
Rev Inst Med Trop São Paulo. 2019;61:e34Page 8 of 10
Due to the highly contagious nature of rotavirus 
particles, factors that affect the probability of contact with 
infectious individuals increase the probability of rotavirus 
infection32. Moreover, it is well known that the possibility 
of rotavirus contaminating objects, toys, and surfaces 
allows the transmission via fomites33. Our results showed 
that kindergarten care of children is significantly related 
to rotavirus positivity (Table 2, p=0.0108). This finding 
is important for assessing the potential risk of infection in 
these care facilities and for effectively designing control 
measures, such as disinfection of surfaces, toys and 
other objects, as has been recently reported for rotavirus 
transmission in household contacts of paediatric patients in 
a USA Surveillance Network that analyzed samples taken 
between 2011-201634.
Although a seasonal trend was reported for G1P[8], 
G2P[4] and G3P[8] rotavirus genotypes previously to the 
introduction of the vaccine in Colombia11, recent analysis 
has failed to find this pattern20. In fact, it has been reported 
that in tropical countries, rotavirus cases usually occur 
year-round, although seasonal peaks may occur in winter35. 
Our sampling period included winter seasons in order to 
include the possible seasonal peak, however this patter was 
not found in our study.
Our study is the first to describe the different genotypes 
present in Northeastern Colombia. The G3 genotype has 
been previously described in other regions of Colombia 
in a lower ratio20 and has been considered as one of the 
historically well-known endemic strains in combination 
with P[8], as we have previously demonstrated36. Our 
results also confirm the presence in Colombia of the 
emerging G9P[8] and G12P[8] strains which have become 
globally important36 and has been recently denoted as 
the predominant rotaviruses in the U.S, in spite of 100% 
vaccination of children37.
It has been postulated that heterotypic strains are being 
selected by vaccination pressure; however, it has not been 
established whether these observations are a result of a 
vaccine-induced immunological pressure or simply reflect 
natural temporal variations in the circulation of rotavirus 
genotypes38. In 2012, the national laboratory in Colombia 
reported that G3 genotypes account only for 3.8% of the 
total genotypes isolated in the country20. Our results show 
a high proportion of G3P[8] strains (Table 3) that may 
suggest the potential of strain divergence, as has been 
previously reported in other Latin American countries39 
and in Europe40. Previous surveillance studies in Colombia 
did not identify any specific patterns in strain prevalence 
that support the “strain replacement hypothesis” after 
the introduction of the monovalent rotavirus vaccine20. 
This result emphasizes the importance of determining 
the relevance of emergent strains and their relationship to 
vaccination in broader population and case-control studies.
In conclusion, we used different protocols and 
laboratory confirmation of rotavirus diarrhoea, including 
genotyping of rotavirus strains, to shown that rotavirus is 
still an important pathogen in children under five years old 
with diarrhoea. The results showed that different factors, 
such as kindergarten attendance, could explain the rotavirus 
A epidemiology and transmission in Bucaramanga. 
The prevalence reported in the study cohort was higher 
compared to previous reports and the genotyping analysis 
of the rotavirus A present in our samples indicated the 
presence of different genotypes, some of them emergent 
and globally important. 
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